NeuroSense Therapeutics Ltd. (NRSN) vs Skye Bioscience, Inc. (SKYE)
A side-by-side comparison of NeuroSense Therapeutics Ltd. and Skye Bioscience, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NRSN
NeuroSense Therapeutics Ltd.
$4.07HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SKYE
Skye Bioscience, Inc.
$1.62HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — NRSN vs SKYE
growth of $100 · dividends reinvested · last 5yNRSN -95.0% (-45.1%/yr)SKYE -98.5% (-57.0%/yr)NRSN compounded faster over this window
NRSN SKYE
NRSN vs SKYE: by the numbers
- •NRSN is the larger company ($7M vs $7M market cap).
Metrics side by side
Profitability
| Metric | NRSN | SKYE |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
Growth (annualized)
| Metric | NRSN | SKYE |
|---|---|---|
| Total return CAGR (5Y) | N/A | -60.42% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.